Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that drive drug discovery and development in oncology and immuno-oncology. We provide a range of integrated solutions, which include preclinical research services, translational platforms, and clinical trial support. Our offer includes the world’s largest commercially available patient-derived xenograft (PDX) collection and over 600 tumor organoid models using Hubrecht Organoid Technology, covering 22 cancer indications. Our expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, we maintain an extensive biobank of liquid and human biospecimens, complete with clinical histories. Operating from 11 facilities in the US, Europe, and APAC—including laboratories accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO)—we ensure the highest standards of quality and reliability in our research environments. For more information, please visit www.crownbio.com. | Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit. Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe, and Asia. Find out more: www.crownbio.com
CrestOptics Spa
CrestOptics S.p.A. is a leading deep tech company specializing in the development and manufacturing of advanced systems for fluorescence microscopy. We provide high-end, flexible solutions like the X-Light Spinning Disk confocal series and the DeepSIM super-resolution module, enabling researchers in the life science, biotech, and pharma industries to achieve faster, high-quality, and high-resolution imaging for groundbreaking biological discoveries.
CRESCOM CO., LTD.
Crescom is a South Korean AI start-up with a primary focus on musculoskeletal X-ray image analysis AI software solutions, the portfolio of which is as follows : – MediAI-BA : Pediatric bone age assessment and adult height prediction with a hybrid GP/TW3 analysis algorithm (0.39 years MAD for analysis accuracy) – MediAI-OA : Quantitative KL grade-based knee osteoarthritis severity analysis (0.83 KL grading detection accuracy) – MediAI-FX : Wrist fraction interpretation on ulna, radius, and scaphoid – MediAI-AS : mSASS score analysis for ankylosing spondylitis (development in progress, but available for free trial) – MediAI-SG : CPAK analysis for lower extremity geometry (for personalized case assessment on knock knees or bowlegs) (development in progress, but available for free trial) – MediAI-SC : Cobb’s angle analysis for scoliosis (development in progress, but available for free trial) | Crescom is a South Korean AI start-up with a primary focus on musculoskeletal X-ray image analysis AI software solutions, the portfolio of which is as follows : // MediAI-BA : Pediatric bone age assessment and adult height prediction with a hybrid GP/TW3 analysis algorithm (0.39 years MAD for analysis accuracy) // MediAI-OA : Quantitative KL grade-based knee osteoarthritis severity analysis (0.83 KL grading detection accuracy) // MediAI-FX : Wrist fraction interpretation on ulna, radius, and scaphoid // MediAI-SG : CPAK analysis for lower extremity geometry (for personalized case assessment on knock knees or bowlegs) // MediAI-SC : Cobb’s angle analysis for scoliosis // MediAI-AS : mSASS score analysis for ankylosing spondylitis (development in progress, but available for free trial)
Creatv Bio
Creatv provides innovative blood tests for detecting and diagnosing cancer when it matters most. Our LifeTracDx® blood test is applicable to all solid tumors, all stages of cancer and all therapies. LifeTracDx® liquid biopsy can screen for cancer and provide prognosis at the same time. • Screen for single cancer or pan cancers even high percentage in stage 1 • Detect minimal residual disease at end of therapy • Detect recurrence earlier than imaging while not requiring tumor to grow larger LifeTracDx® liquid biopsy can also provide diagnostics for patients with cancer. • Provide companion/complementary diagnostics – simpler and cheaper than tissue biopsy, such as immunotherapy • Provide prognosis at any time • Predict treatment response to new therapy just 30 days after first treatment • Monitor therapy identification of drug resistance • Provide copious unfragmented tumor DNA for sequencing Clinical applications of these highly sensitive and specific tests will reduce morbidity and significantly improve patient outcomes. Our LifeTracDx® blood test will not only benefit patients, but also ideally suited for cancer drug development and clinical trials.
Creative Biomart Inc
Creative BioMart is a leading biotech company that provides innovative products and services to the scientific community worldwide. We specialize in developing and manufacturing high-quality recombinant proteins, and custom services for life science research, drug discovery, and diagnostic applications. We pride ourselves on our customer-centric approach, which ensures our customers receive exceptional service and support at every stage of their research project. Whether you need any help, our team is always available to help.
Countable Labs
Countable Labs (formerly Enumerix) is redefining PCR with single-molecule precision and category-defining sensitivity, overcoming the limitations of other PCR and next-generation sequencing approaches. The company’s Countable PCR technology delivers at least 10 times the sensitivity and precision of other PCR technologies in a single reaction. Plus, Countable PCR’s single-molecule isolation enables 10-color multiplexing and simplifies assay development. Founded in 2019 by Stephen Fodor, Ari Chaney, and Christina Fan, Countable Labs is privately held and supported by leading life sciences tools investors including ARCH Venture Partners and F-Prime Capital. The company is headquartered in Palo Alto, Calif.
Cornell University, Center for Life Science Ventures & CAT
The Center for Life Science Ventures was founded in 2008 as a startup incubator to help develop young Cornell life science companies. The Center is funded through the Office of the Vice President for Research and Innovation, the Institute of Biotechnology and NYSTAR. The Center’s program focuses on accelerating research and development of its client’s companies’ technology and products, validating its client companies’ business plans, and strengthening their management teams. The Center’s goal is to facilitate the forward progress of client companies to the point where each will merit significant outside investment, and achieve self-sufficiency. In doing so, the Center for Life Science Ventures contributes to the University’s mission as New York State’s Morrill Land Grant institution to support local, regional, and state-wide Life Sciences jobs/economic development.
CorDx
CorDx manufactures point-of-care and over-the-counter rapid diagnostic products across a variety of categories, including infectious disease, reproductive & sexual health, substance abuse, and other health and marker tests. With authorization for use in the US (FDA), Europe (CE Mark) and China (NMPA), CorDx tests are known for their comfort, speed and accuracy. The flagship three-in-one test for Flu A/B & COVID-19 features a more comfortable synthetic nasal swab and provides reliable results in just 10 minutes. Since 2006, CorDx has developed diagnostic products while establishing a solid supply chain foundation, allowing it to provide better quality, more affordable tests for distributors, healthcare providers and patients alike. CorDx is a CorDx Union company, a biotechnology organization that delivers medical device solutions to healthcare industries and over a billion users in more than 170 countries. CorDx Union provides full-cycle support from life’s conception to its completion. Outside of healthcare, CorDx Union propels innovations in energy, AI quality management, and other platforms. Each member plays an important role in the CorDx ecosystem, all anchored around a vertically integrated supply chain that ensures users have access to the products they need when they need them.
Cor.Sync
Cor.Sync is a solution for fast and accurate heart attack diagnosis at the hospital emergency care. Myocardial infarction, also known as heart attack, is one of the biggest causes of death around the world. But its diagnosis requires, along with electrocardiogram, a blood test to measure a biomarker, called troponin. Nowadays it takes from 1 to 5 hours to measure troponin at laboratories, and half of the deaths by infarction happens inside hospital, while the patient is waiting for these results. Cor.Sync is a point of care testing platform, with a desktop device and biosensors, capable of measuring troponin in just 8 minutes with the same accuracy and price as a laboratory test.
ContextVision
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X -ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. Building on more than 40 years of leadership in medical image enhancement, ContextVision is advancing its legacy through the transformation to Data Quality— a focused ultrasound program that leverages AI-powered image-enhancements to enable organ and disease specific quantitative imaging solutions to point-of-care ultrasound. The goal is to deliver a more rapid and accurate detection as well as staging of chronic conditions, such as MASLD (Metabolic dysfunction-associated steatotic liver disease). By combining organ-specific image enhancement, user-independent workflows, as well as quantitative disease-specific digital biomarkers, the platform is being built to support near-patient diagnostic solutions.